Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results

Press Release Apr 11 2024 FORE Biotherapeutics presenting at Stifel 2024 Virtual Targeted Oncology Forum Read more

Press Release Apr 09 2024 FORE Biotherapeutics announces new nonclinical data highlighting the differentiation of plixorafenib in combination with MEK inhibition at #AACR24 Read more

Press Release Feb 29 2024 FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer Read more